Semaglutide (Novo Nordisk)

CAMBRIDGE, Mass., May 11, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that a late-breaking abstract highlighting DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors for the treatment of obesity, has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) Congress 2026, being held May 27–30, 2026 in Barcelona, Spain. "Having a late-breaking abstract on DA-1726 accepted for a poster presentation at the prestigious EASL Congress underscores the strength of this asset," stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "DA-1726 continues to demonstrate potential for a differentiated, best-in-class profile and is currently being evaluated in a 16-week Phase 1 Part 3 titration study designed to optimize higher dose levels and tolerability, with data expected in the fourth quarter of this year." Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DA-1726, an Oxyntomodulin Analogue, in a Higher-Dose Phase 1 Cohort with Exploratory Noninvasive Liver Assessment Presenting Author: Chris Fang, Chief Medical Officer, MetaVia Abstract Number: LB26-5204 Final Abstract ID: LBP-010 Session: Late Breaking Posters Presentation Date: Wednesday, May 27, 2026 Presentation Start: 8:30 am CET A copy of the poster will be available on the Posters section of the MetaVia website after the presentation. About DA-1726 DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is to be administered once weekly subcutaneously. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. DA-1726 has a well understood mechanism and, in pre-clinical mice models, resulted in improved weight loss compared to semaglutide (Wegovy®), a leading GLP-1 receptor agonist. Additionally, in pre-clinical mouse models, DA-1726 elicited similar weight reduction, while consuming more food, compared to tirzepatide (Zepbound®) and survodutide (a drug with the same MOA), while also preserving lean body mass and demonstrating improved lipid-lowering effects compared to survodutide. In the Phase 1 multiple ascending dose (MAD) trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist circumference reduction. About MetaVia MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists such as semaglutide. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. For more information, please visit . Forward Looking Statements Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Contacts: MetaVia Marshall H. Woodworth Chief Financial Officer +1-857-299-1033 [email protected] Rx Communications Group Michael Miller +1-917-633-6086 [email protected] SOURCE MetaVia Inc. 21% more press release views with Request a Demo

AUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) have become two of the most pressing healthcare challenges worldwide, driving rising rates of cardiovascular disease, fatty liver disease, kidney complications and escalating healthcare costs. What began as a niche class of diabetes medications has evolved into one of the most transformative therapeutic categories in modern medicine, with GLP-1 receptor agonists now reshaping obesity treatment, metabolic care and potentially even neurodegenerative disease management. Against this backdrop, SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), (profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history. SureNano is one of the emerging microcap companies operating in the GLP space, forming part of a group of companies leading the way in the GLP-1 space, including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE). As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine. SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine. Click here to view the custom infographic of the SureNano Science editorial. GLP-1 Therapies Reshape Global Healthcare The global obesity crisis continues to intensify. According to the World Health Organization, an estimated one billion people worldwide are living with obesity, while rates of type 2 diabetes continue to rise across both developed and emerging economies. The WHO further notes that obesity significantly increases the risk of cardiovascular disease, stroke and type 2 diabetes, while additional research has linked excess weight to chronic kidney disease and rising healthcare expenditures, creating substantial pressure on healthcare systems globally. GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine. Originally developed for blood glucose regulation in diabetes patients, these therapies are now widely recognized for their ability to produce meaningful weight loss and improve broader metabolic outcomes. Industry leaders Novo Nordisk A/S and Eli Lilly and Company currently dominate the market through blockbuster injectable products including Ozempic(R), Wegovy(R), Mounjaro(R) and Zepbound(R). Commercial expectations surrounding this sector continue to accelerate. JPMorgan Chase & Co. projects the broader obesity drug market could approach $200 billion by 2030 as adoption expands globally and indications broaden beyond diabetes and weight management. Additional industry forecasts suggest GLP-1 therapies could become one of the most commercially successful pharmaceutical categories in history, with annual sales projections reaching $150 billion or more by the end of the decade. At the same time, the industry is already shifting toward next-generation incretin therapies focused on improving efficacy, tolerability and convenience. Oral formulations, expanded indications and combination metabolic therapies are becoming major priorities across the pharmaceutical sector. Within this evolving landscape, SureNano Science is positioning itself as an agile entrant pursuing differentiated innovation through GEP-44, a patented triple agonist peptide licensed from Syracuse University and designed to advance through the U.S. Food and Drug Administration (FDA) regulatory pathway. A Differentiated Next-Generation GLP Candidate SureNano Science is advancing GEP-44 as a patented, next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs, positioning this emerging microcap as a minnow among giants quickly transitioning through the FDA pathway. Unlike conventional GLP-1 agonists that primarily target a single receptor pathway, GEP-44 functions as a triple agonist targeting GLP-1 and peptide YY receptors Y1 and Y2. This integrated mechanism is designed to simultaneously regulate glucose metabolism, suppress appetite and improve tolerability within a single molecule. The compound was developed at Syracuse University and has demonstrated encouraging preclinical results. According to the company, GEP-44 produced meaningful reductions in food intake and body weight while also improving glycemic control in preclinical studies. Importantly, the compound reportedly avoided the nausea and gastrointestinal side effects commonly associated with many first-generation GLP-1 therapies, a factor that could become increasingly important as patient adoption expands. The broader pharmaceutical industry is aggressively pursuing differentiated incretin therapies capable of addressing patient tolerability and adherence challenges. PwC notes that the next phase of the obesity drug market will likely be defined by expanded indications, improved delivery methods and therapies offering better long-term patient adherence. This creates a favorable backdrop for companies pursuing second-generation GLP innovation. While smaller than major pharmaceutical incumbents, SureNano Science operates with a lean development structure and cost-efficient strategy designed to maximize flexibility and accelerate development timelines. The company conducts significant research activities in Australia, where government incentives may provide research tax credits of up to 43.5% on eligible expenditures. If GEP-44 continues to demonstrate positive outcomes through future clinical development, the company could position itself as a potential acquisition, licensing or partnership candidate within the rapidly expanding GLP ecosystem. Positioned Within Massive Market Expansion The commercial opportunity surrounding GLP-1 therapies continues to grow rapidly. According to Morgan Stanley, the global GLP-1 market could approach $190 billion by 2035 as patient adoption expands and broader therapeutic applications emerge. Industry forecasts from BCC Research similarly projects substantial long-term growth — $268.4 billion by 2030 — in the GLP-1 analogue market through the end of the decade. Patient adoption is also accelerating. Estimates suggest that anywhere from 25 to 30 million Americans could be using GLP-1 therapies by 2030, compared with approximately 10 million users in 2026. Expanding insurance coverage, rising obesity prevalence and broader physician adoption are all contributing to the rapid mainstream acceptance of these therapies. The competitive landscape is simultaneously evolving toward next-generation products. IQVIA describes 2026 as potentially becoming the “year of the orals,” with oral GLP-1 formulations expected to significantly improve accessibility, adherence and long-term maintenance therapy adoption. Off-patent semaglutide expansion across major global markets is also expected to increase competition and broaden overall patient access. As GEP-44 advances through IND-enabling studies and toward eventual phase I trials, SureNano Science represents one of the relatively few microcap public companies providing direct exposure to the rapidly expanding GLP-1 market. This creates a potential valuation disconnect compared with large-cap pharmaceutical incumbents and later-stage obesity therapy developers, particularly if the company successfully achieves meaningful clinical and regulatory milestones. Advanced Delivery Technologies Expand Opportunity Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence. The company’s platform strategy includes evaluating oral, sublingual and intranasal delivery approaches that could eventually reduce dependence on injectable therapies. Convenience and adherence are becoming increasingly important competitive factors within the GLP-1 market. Current market-leading therapies are primarily injectable, which can create barriers for some patients due to administration complexity, refrigeration requirements and long-term compliance challenges. Oral and noninvasive alternatives are widely viewed as one of the next major commercial opportunities within obesity and diabetes therapeutics. Industry analysts increasingly believe delivery innovation could become just as important as efficacy itself. IQVIA notes that oral obesity therapies could dramatically improve long-term maintenance adoption while simplifying distribution logistics by eliminating cold-chain requirements. This could significantly expand patient accessibility across international markets. By combining therapeutic development with delivery innovation, SureNano Science is building a vertically integrated metabolic disease platform rather than focusing solely on a single injectable drug candidate. This broader platform strategy may create additional long-term optionality and commercial flexibility as the obesity treatment market continues evolving. Preclinical Results Highlight Competitive Potential Preclinical data released by SureNano Science suggest that GEP-44 may offer meaningful differentiation compared with earlier-generation GLP therapies, positioning the company for meaningful upside as it progresses through its development phases of the FDA approval pathway. According to the company, the compound demonstrated approximately 15% weight loss in preclinical testing compared with roughly 9% observed with liraglutide, while food intake reductions approached 39% versus approximately 20% for the comparator. In addition to weight reduction, GEP-44 also demonstrated improved glycemic control while reportedly avoiding nausea and vomiting during testing. Gastrointestinal side effects remain one of the most significant challenges associated with many currently marketed GLP-1 therapies and are a major factor affecting long-term patient adherence. Improved tolerability could therefore become an important competitive advantage if these findings translate successfully into clinical studies. The pharmaceutical industry continues investing heavily into next-generation obesity therapies capable of improving efficacy and patient experience. The Pharma Letter reports that obesity drug pipelines are increasingly focused on differentiation through combination pathways, enhanced tolerability and expanded delivery approaches as competition intensifies. While GEP-44 remains in preclinical development, these early findings position SureNano Science within a highly strategic segment of the obesity treatment landscape. If future studies continue validating these results, the company could emerge as a differentiated participant in one of the largest and fastest-growing therapeutic categories in modern healthcare. Strategic Expansion Creates Future Optionality In addition to advancing its core GLP-1 metabolic disease platform, SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio. These discussions include nonbinding opportunities involving ibogaine-related intellectual property focused on formulation and delivery technologies. While still exploratory and not considered a core asset at this stage, the initiative reflects a broader strategy aimed at building diversified platform capabilities across multiple high-growth therapeutic areas. Interest in ibogaine and related psychedelic-based therapeutics has increased significantly in recent years as researchers investigate their potential applications in addiction treatment, mental health disorders and neurological conditions. CNN recently reported growing scientific and regulatory attention surrounding ibogaine research, particularly in areas involving opioid addiction and treatment-resistant mental health conditions. At the same time, the U.S. Food and Drug Administration has signaled increasing interest in accelerating development pathways for treatments targeting serious mental illnesses and unmet medical needs. SureNano’s interest in formulation and delivery technologies within these emerging areas aligns with the company’s broader emphasis on drug-delivery innovation and platform flexibility. Rather than positioning ibogaine-related opportunities as a standalone commercial focus, the company appears to be evaluating how specialized delivery technologies and intellectual property could complement its existing expertise in metabolic therapeutics and nontraditional administration approaches. This type of optionality may provide additional long-term strategic value if regulatory environments surrounding psychedelic-based therapies continue to evolve favorably. These initiatives remain early stage and subject to substantial scientific, clinical and regulatory uncertainty. However, by evaluating selective expansion opportunities alongside its primary GLP-1 development efforts, SureNano Science is positioning itself within a broader trend toward diversified therapeutic platforms capable of addressing multiple large and evolving healthcare markets. As pharmaceutical innovation increasingly converges around metabolic health, neuroscience and advanced delivery technologies, strategic flexibility could become an increasingly valuable differentiator for emerging biotechnology companies. GLP-1 Market Enters New Phase The GLP-1 sector continues to evolve rapidly as pharmaceutical developers expand treatment options for obesity, diabetes and related metabolic conditions. Recent advancements across the space highlight growing momentum behind next-generation oral therapies, long-acting injectable formulations and reduced-frequency dosing approaches designed to improve patient convenience, broaden access and enhance long-term treatment outcomes in one of healthcare’s fastest-growing therapeutic markets. Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) approved Foundayo(TM) (orforglipron) for adults with obesity or who are overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo will be available via LillyDirect(R), with prescriptions accepted immediately and shipping beginning April 6, followed shortly after with broad availability through U.S. retail pharmacies and telehealth providers. Novo Nordisk A/S (NYSE: NVO) announced that Ozempic(R) (semaglutide) tablets 1.5 mg, 4 mg and 9 mg will be available for adults with type 2 diabetes in the United States. Ozempic is the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes indicated not only to improve blood sugar, along with diet and exercise, but also to reduce the risk of major cardiovascular events (MACE) such as heart attack, stroke or death in those who are also at high risk for these events. Amgen Inc. (NASDAQ: AMGN) is reporting full results from part 1 of the phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. In addition to these data, complete results from the primary analysis of the phase 1 pharmacokinetics low-dose initiation (PK-LDI) study evaluating lower starting doses of MariTide were presented as part of an expert-led symposium at the 85th American Diabetes Association (ADA) Scientific Sessions and simultaneously published in “The New England Journal of Medicine.” Pfizer Inc. (NYSE: PFE) announced positive topline results from the phase 2b VESPER-3 study investigating monthly maintenance dosing of its fully-biased, ultra-long-acting, injectable GLP-1 receptor agonist (RA) PF’3944 (MET-097i) in adults with obesity or overweight without type 2 diabetes. The study had two objectives: to demonstrate PF’3944 could achieve continued weight loss when switching from weekly to monthly subcutaneous injections and maintain its efficacy while reducing the dosing frequency four-fold and to demonstrate PF’3944 could switch to a four-fold equivalent monthly dose while maintaining a well-tolerated and favorable safety profile. These key announcements underscore the continued transformation of the metabolic disease landscape, where innovation is increasingly focused on efficacy, accessibility and patient adherence. As competition intensifies and new formulations move through regulatory and clinical milestones, the GLP-1 market is poised to remain a major driver of growth and innovation across the broader pharmaceutical industry. For more information, visit SureNano Science. About BioMedWire BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness. BMW is where breaking news, insightful content and actionable information converge. To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or republished: https://wwwBioMedWire.com/Disclaimer BioMedWireAustin, Texaswww.BioMedWire.com512.354.7000 OfficeEditor@BioMedWire.com BioMedWire is powered by IBN